GLP-1 Agonists in Pregnancy: What Clinicians Must Know
Currently, clinical discussions around GLP-1 agonists in pregnancy have become increasingly common. Millions of reproductive-aged women use these agents to manage obesity and type 2 diabetes. In addition, these medications promote significant weight reduction and metabolic improvements. Consequently, restored ovulatory function often leads to unintended pregnancies.
Evidence on GLP-1 Agonists in Pregnancy
A recent narrative review evaluated maternal and fetal outcomes after inadvertent conception exposure. Specifically, researchers analyzed global observational studies and pharmacokinetic data. Overall, available human evidence does not show a clear rise in congenital anomalies. Furthermore, researchers found no definite increase in stillbirth or miscarriage rates. However, existing studies rely primarily on retrospective registries and modest cohort sizes. Therefore, clinicians cannot completely rule out subtle fetal or maternal risks.
Pharmacokinetics and Washout Recommendations
Most manufacturers currently advise stopping these medications prior to planned conception. For instance, semaglutide has an elimination half-life of roughly seven days. Consequently, guidelines suggest a two-month washout period before conception. Similarly, tirzepatide requires discontinuation at least one month before pregnancy attempts. Moreover, delayed gastric emptying from GLP-1 receptor agonists can disrupt oral contraceptive absorption. As a result, healthcare providers should recommend barrier methods or intrauterine devices.
Practical Counselling and Clinical Next Steps
When an unintended pregnancy occurs, clinicians must remain supportive and objective. First, patients should immediately discontinue the medication upon pregnancy confirmation. Next, clinicians should evaluate glycemic control and maternal metabolic stability. In addition, obstetricians should schedule detailed early anatomical ultrasound scans. Clinicians should reassure anxious mothers that current data show no distinct teratogenic pattern. Nonetheless, individualised risk assessment remains vital for every exposed pregnancy.
Frequently Asked Questions
Q1: Should a woman terminate a pregnancy due to inadvertent GLP-1 exposure?
No, available clinical evidence does not justify terminating an otherwise wanted pregnancy.
However, the patient should stop the medication immediately and seek obstetric assessment.
Q2: How long should women discontinue GLP-1 therapies before conception?
Most clinical guidelines recommend discontinuing semaglutide at least two months prior to conception.
Furthermore, shorter-acting agents like liraglutide require at least a few days of washout.
Q3: Do GLP-1 receptor agonists cause congenital malformations?
Current human registry data show no clear increase in major birth defects.
Nevertheless, prospective studies must confirm long-term fetal safety.
References
- Lau KGY et al. Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes. BJOG. 2026 Oct 04. doi: 10.1111/1471-0528.70339. PMID: 42830218.
- Khalil A et al. Periconception GLP-1 exposure and pregnancy outcomes: a systematic review and meta-analysis. Med. 2026; doi: 10.1016/j.medj.2026.09.004.
- Brown J et al. GLP-1 receptor agonist use during early pregnancy and risk of adverse pregnancy outcomes. Ann Intern Med. 2026;179(7):891-901.
